Online inquiry

IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12873MR)

This product GTTS-WQ12873MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TLR2 gene. The antibody can be applied in Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001318787.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7097
UniProt ID O60603
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ12873MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15431MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TSR-033
GTTS-WQ11808MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MK-3475
GTTS-WQ9624MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ3417MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aALB03
GTTS-WQ15723MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA VIR-7831
GTTS-WQ6996MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA F-627
GTTS-WQ11001MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ14107MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aNGF75
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW